IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study

Clinical trial NCT07493486 · COMPLETED

Trial details

NCT number: NCT07493486
Sponsor: Zhejiang Cancer Hospital
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Diffuse Large B-Cell Lymphoma (DLBCL)Intrathecal Chemotherapy

Start date: 2022-02-01
Primary completion: 2023-08-31
Enrollment: 31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.